ASP Isotopes (NASDAQ:ASPI) Insider Paul Elliot Mann Sells 112,500 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) insider Paul Elliot Mann sold 112,500 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $7.51, for a total value of $844,875.00. Following the sale, the insider owned 7,971,691 shares of the company’s stock, valued at approximately $59,867,399.41. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Paul Elliot Mann also recently made the following trade(s):

• On Tuesday, November 25th, Paul Elliot Mann sold 50,000 shares of ASP Isotopes stock. The shares were sold at an average price of $5.77, for a total transaction of $288,500.00.
• On Monday, September 8th, Paul Elliot Mann sold 81,076 shares of ASP Isotopes stock. The stock was sold at an average price of $8.53, for a total value of $691,578.28.
• On Tuesday, September 9th, Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock. The shares were sold at an average price of $8.39, for a total value of $680,236.03.

ASP Isotopes Trading Up 4.7%

NASDAQ:ASPI traded up $0.28 on Friday, reaching $6.20. 3,023,365 shares of the stock traded hands, compared to its average volume of 6,870,618. The company’s 50 day moving average is $9.19 and its 200-day moving average is $8.78. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04. ASP Isotopes Inc. has a 1-year low of $3.65 and a 1-year high of $14.49. The firm has a market capitalization of $687.10 million, a price-to-earnings ratio of -4.77 and a beta of 3.28.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $2.25 million. ASP Isotopes had a negative return on equity of 190.44% and a negative net margin of 1,259.12%. Equities research analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ASPI has been the subject of several recent analyst reports. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a research note on Monday, October 27th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, ASP Isotopes presently has an average rating of “Hold” and a consensus target price of $13.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in ASP Isotopes by 13.0% in the 1st quarter. Bank of New York Mellon Corp now owns 142,257 shares of the company’s stock valued at $667,000 after acquiring an additional 16,383 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of ASP Isotopes by 4.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 165,364 shares of the company’s stock valued at $776,000 after purchasing an additional 7,138 shares during the period. Deutsche Bank AG lifted its stake in shares of ASP Isotopes by 19.4% during the 1st quarter. Deutsche Bank AG now owns 40,092 shares of the company’s stock valued at $188,000 after buying an additional 6,505 shares in the last quarter. Rovida Investment Management Ltd boosted its holdings in ASP Isotopes by 59.8% in the 1st quarter. Rovida Investment Management Ltd now owns 350,000 shares of the company’s stock worth $1,620,000 after buying an additional 131,028 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of ASP Isotopes during the first quarter worth $615,000. Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.